A subset of CD45+/CD19-cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma

作者：Kim Sung Min; Lee Seung Tae; Ryu Kyung Ju; Kim Hee Jin; Kim Sun Hee; Ko Young Hye; Kim Won Seog; Kim Seok Jin^*

来源：Leukemia and Lymphoma, 2015, 56(11): 3052-3057.

DOI：10.3109/10428194.2015.1025391

• Cancer stem cell
• mantle cell lymphoma
• bone marrow

Mantle cell lymphoma has features of both indolent and aggressive non-Hodgkin lymphomas. Repeated relapses leading to treatment failure in patients with mantle cell lymphoma might suggest the presence of cancer stem cells. A small cell population with CD45+/CD19 - was previously reported to represent cancer stem cells. We evaluated the clinical relevance of CD45+/CD19 - cells in bone marrow of patients with mantle cell lymphoma (n = 20). A CD45+/CD19 - cell population was observed in newly diagnosed mantle cell lymphoma, and its percentage correlated with tumor cells in bone marrow (r = 0.832, p = 0.001) and score on the simplified mantle cell lymphoma prognostic index (r = 0.675, p = 0.016). After treatment, CD45+/CD19 - cells decreased (mean: 0.012%), and CD45+/CD19 - cells (0.276%) were higher at relapse or progression than at diagnosis. In conclusion, a CD45+/CD19 - cell population in bone marrow aspirates correlated with the clinical outcome of patients with mantle cell lymphoma.

• 出版日期2015-11-2